Extrapyramidal side effects in a blue and gold macaw (Ara ararauna) treated with haloperidol and clomipramine

Journal of Avian Medicine and Surgery

Volumn 22, Issue 3, 2008, Pages 234-239

  Starkey, Simon R ^a   Morrisey, James K ^a   Hickam, Hillary D ^b   Albright, Julia D ^a   Lynch, Mary J ^a  

^a Cornell University ^*  (United States)

^b Animal Surgical and Emergency Center   (United States)

Author keywords

Ara ararauna; Avian; Blue and gold macaw; Clomipramine; Dystonia; Extrapyramidal side effects; Haloperidol

Indexed keywords

CLOMIPRAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; SEROTONIN UPTAKE INHIBITOR;

ANIMAL; ARTICLE; BIRD DISEASE; CASE REPORT; CHEMICALLY INDUCED DISORDER; EXTRAPYRAMIDAL SYNDROME; FEMALE; PSITTACINE;

ANIMALS; BASAL GANGLIA DISEASES; BIRD DISEASES; CLOMIPRAMINE; DOPAMINE ANTAGONISTS; FEMALE; HALOPERIDOL; PSITTACIFORMES; SEROTONIN UPTAKE INHIBITORS;

ARA ARARAUNA; AVES; PSITTACIDAE;

EID: 55949129989     PISSN: 10826742     EISSN: None     Source Type: Journal    
DOI: 10.1647/2007-037.1     Document Type: Article

References (50)

1. Leo RJ. Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry. 1996;57:449-454.
2. Shirzadi AA, Ghaemi SN. Side effects of atypical antipsychotics: extrapyramidal symptoms and the metabolic syndrome. Harv Rev Psychiatry. 2006; 14:152-164.
3. Carpenter JW. Exotic Animal Formulary. 3rd ed. St Louis, MO: Elsevier Saunders; 2005.
4. Dell'Osso B, Nestadt G, Allen A, Hollander E. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: a critical review. J Clin Psychiatry. 2006;67:600-610.
5. Eddy KT, Dutra L, Bradley R, Westen D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev. 2004;24:1011-1030.
6. Houghton WC, Scammell TE, Thorpy M. Pharmacotherapy for cataplexy. Sleep Med Rev. 2004;8: 355-366.
7. McTavish D, Benfield P. Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder. Drugs. 1990;39: 136-153.
8. Lotufo-Neto F, Bernik M, Ramos RT, et al. A dose-finding and discontinuation study of clomipramine in panic disorder. J Psychopharmacol. 2001; 15:13-17.
9. Denys D. Pharmacotherapy of obsessive-compulsive disorder and obsessive-compulsive spectrum disorders. Psychiatr Clin North Am. 2006;29:553-584.
10. Benfield DP, Harries CM, Luscombe DK. Some pharmacological aspects of desmethylclomipramine. Postgrad Med J. 1980;56(suppl 1):13-18.
11. Maj J, Stala L, Gorka Z, Adamus A. Comparison of the pharmacological actions of desmethylclomipramine and clomipramine. Psychopharmacology (Berl). 1982;78:165-169.
12. Austin LS, Lydiard RB, Ballenger JC, et al. Dopamine blocking activity of clomipramine in patients with obsessive-compulsive disorder. Biol Psychiatry. 1991;30:225-232.
13. Egberts AC, Meyboom RH, De Koning FH, et al. Non-puerperal lactation associated with antidepressant drug use. Br J Clin Pharmacol. 1997;44: 277-281.
14. Ulloa RE, Nicolini H, Fernandez-Guasti A. Age differences in an animal model of obsessive-compulsive disorder: participation of dopamine: dopamine in an animal model of OCD. Pharmacol Biochem Behav. 2004;78:661-666.
15. Denys D, van der Wee N, Janssen J, et al. Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder. Biol Psychiatry. 2004;55:1041-1045.
16. Hart BL, Cliff KD, Tynes VV, Bergman L. Control of urine marking by use of long-term treatment with fluoxetine or clomipramine in cats. J Am Vet Med Assoc. 2005;226:378-382.
17. Landsberg GM, Wilson AL. Effects of clomipramine on cats presented for urine marking. J Am Anim Hosp Assoc. 2005;41:3-11.
18. Overall KL, Dunham AE. Clinical features and outcome in dogs and cats with obsessive-compulsive disorder: 126 cases (1989-2000). J Am Vet Med Assoc. 2002;221:1445-1452.
19. Hewson CJ, Conlon PD, Luescher UA, Ball RO. The pharmacokinetics of clomipramine and desmethylclomipramine in dogs: parameter estimates following a single oral dose and 28 consecutive daily oral doses of clomipramine. J Vet Pharmacol Ther. 1998;21:214-222.
20. King JN, Maurer MP, Altmann BO, Strehlau GA. Pharmacokinetics of clomipramine in dogs following single-dose and repeated-dose oral administration. Am J Vet Res. 2000;61:80-85.
21. Lainesse C, Frank D, Meucci V, et al. Pharmacokinetics of clomipramine and desmethylclomipramine after single-dose intravenous and oral administrations in cats. J Vet Pharmacol Ther. 2006;29: 271-278.
22. Ramsay EC, Grindlinger H. Use of clomipramine in the treatment of obsessive behavior in psittacine birds. J Assoc Avian Vet. 1994;8:9-15.
23. Ritchie BW, Harrison GJ. Formulary. In: Ritchie BW, Harrison GJ, Harrison LR, eds. Avian Medicine and Surgery. Lake Worth, FL: Wingers Publishing; 1994:457-479.
24. Seibert LM, Crowell-Davis SL, Wilson GH, Ritchie BW. Placebo-controlled clomipramine trial for the treatment of feather picking disorder in cockatoos. J Am Anim Hasp Assoc. 2004;40:261-269.
25. Juarbe-Diaz SV. Animal behavior case of the month: Congo African grey parrot examined because of feather picking and self-injurious behavior. J Am Vet Med Assoc. 2000;216:1562-1564.
26. Ackerman DL, Greenland S, Bystritsky A, Katz J. Relationship between early side effects and therapeutic effects of clomipramine therapy in obsessivecompulsive disorder. J Clin Psychopharmacol. 1996;16:324-328.
27. Fujishiro J, Imanishi T, Onozawa K, Tsushima M. Comparison of the anticholinergic effects of the serotonergic antidepressants, paroxetine, fluvoxamine and clomipramine. Eur J Pharmacol. 2002; 454:183-188.
28. Stage KB, Kragh-Sørensen P. Danish University Antidepressant Group. Age-related adverse drug reactions to clomipramine. Acta Psychiatr Scand. 2002; 105:55-59.
29. Schillevoort I, van Puijenbroek EP, de Boer A, et al. Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a casecontrol study using spontaneous reports. Int Clin Psychopharmacol. 2002; 17:75-79.
30. Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol. 1998; 12:192-214.
31. Broich K, Grunwald F, Kasper S, et al. D2-dopamine receptor occupancy measured by IBZM-SPECT in relation to extrapyramidal side effects. Pharmacopsychiatry. 1998;31:159-162.
32. Kapur S, Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996; 153:466-476.
33. Seksel K, Lindeman MJ. Use of clomipramine in the treatment of anxiety-related and obsessive-compulsive disorders in cats. Aust Vet J. 1998;76:317-321.
34. Kapur S, Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1081-1090.
35. Hadamitzky M, Harich S, Koch M, Schwabe K. Deficient prepulse inhibition induced by selective breeding of rats can be restored by the dopamine D2 antagonist haloperidol. Behav Brain Res. 2007; 177:364-367.
36. Kufferle B, Tauscher J, Asenbaum S, et al. IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psychopharmacology (Berl). 1997; 133:323-328.
37. Marsden CD, Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med. 1980; 10:55-72.
38. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract. 2007; 13: 13-24.
39. James LP, Abel K, Wilkinson J, et al. Phenothiazine, butyrophenone, and other psychotropic medication poisonings in children and adolescents. Clin Toxicol. 2000;38:615-623.
40. Margolese HC, Chouinard G, Kolivakis TT, et al. Tardive dyskinesia in the era of typical and atypical antipsychotics, part 1: pathophysiology and mechanisms of induction. Can J Psychiatry. 2005;50: 541-547.
41. Heintz R, Casey DE. Pargyline reduces/prevents neuroleptic-induced acute dystonia in monkeys. Psychopharmacology (Berl). 1987;93:207-213.
42. Poyurovsky M, Weizman A. Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: a new approach to an old problem. Br J Psychiatry. 2001; 179:4-8.
43. Lennox AM, VanDerHeyden N. Long term use of haloperidol in two parrots. Proc Annu Conf Assoc Avion Vet. 1999:133-137.
44. Duggal HS, Dutta S, Sinha VK. Clomipramine discontinuation-emergent dystonia. Aust N Z J Psychiatry. 2001;35:696.
45. Stoukides JA, Stoukides CA. Extrapyramidal symptoms upon discontinuation of fluoxetine. Am J Psychiatry. 1991; 148:1263.
46. Dilsaver SC. Withdrawal phenomena associated with antidepressant and antipsychotic agents. Drug Saf. 1994;10:103-114.
47. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol. 1996; 16:356-362.
48. Gill HS, DeVane CL, Risch SC. Extrapyramidal symptoms associated with cyclic antidepressant treatment: a review of the literature and consolidating hypotheses. J Clin Psychopharmacol. 1997; 17:377-389.
49. Gerber PE, Lynd LD. Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother. 1998;32:692-698.
50. Leo RJ. Movement disturbances associated with the use of selective serotonin-reuptake inhibitors. Ann Pharmacother. 1998;32:712-714.